Member Info for RayPointer

https://www.scancell.co.uk/Data/Sites/1/media/publications/papers/tivadar-et-al-2020.pdf

Actually the full article explains that the antibody-drug conjugation was achieved by means other than Avidimab (see section on "Drug conjugation")
I guess this research must have been done pre-Avidimab discovery. IMO it seems likely that Lindy would now be looking to use Avidimab instead.

Well we know that Lindy has a special interest in pancreatic cancer and at least one of the glycan mAbs targets it.

https://www.scancell.co.uk/monoclonal-antibody-targeting-sialyl-di-lewisa%E2%80%93-containing-internalizing-and-noninternalizing-glycoproteins-with-cancer-immunotherapy-development-potential

"FG129 targets 74% (135/182) of pancreatic, 50% (46/92) of gastric, 36% (100/281) of colorectal, 27% (89/327) of ovarian, and 21% (42/201) of non–small cell lung cancers, by IHC. In our pancreatic cancer cohort, high FG129 glyco-epitope expression was significantly associated with poor prognosis (P ¼ 0.004). Crucially, the glyco-epitope displays limited normal tissue distribution, with FG129 binding weakly to a small percentage of cells within gallbladder, ileum, liver, esophagus, pancreas, and thyroid tissues. Owing to glyco-epitope internalization, we validated payload delivery by CH129 through monomethyl auristatin E (MMAE) or maytansinoid (DM1 and DM4) conjugation. All three CH129 drug conjugates killed high-binding colorectal and pancreatic cancer cell lines with (sub)nanomolar potency, coinciding with significant in vivo xenograft tumor control by CH129-vcMMAE. CH129, with its restricted normal tissue distribution, avid tumor binding, and efficient payload delivery, is a promising candidate for the treatment of sialyl-di-Lewisa– expressing solid tumors, as an antibody–drug conjugate or as an alternative cancer immunotherapy modality."

Note "avid tumor binding, and efficient payload delivery". The antibody-drug conjugation is presumably facilitated by attaching the drug to the Avidimab structure.

blue!

C7, I really thought you would have clue tiles :-)

Lindy attends conferences to present on Scancell's science, not to announce news.
The 2 have never been linked in my experience.

News about the SCIB1 combo trial restarting could happen at any time. It is mainly about predicting the likely future impact by Covid19 on hospital resources.
For the Modi1 trial starting, this may be preceded by an RNS about the completion of the manufacture.

For Covidity who knows when news will come and what the content will be. It could be the completion of the delivery system, completion of the manufacture, P1 trial starting, more funding, a deal with CEPI or any combination of these in 1 RNS.

It's almost left field now but we could hear of developments on the Glycans/Avidimab front. Remember no less than 3 companies were in collaboration with Scancell.

Then, sticking to left field, there is Lindy's work for continuum. We are told that there will be an exciting announcement soon. Will it involve Lindy finding some more important cancer targets?

Then, if that's not enough, Lindy has apparently found important targets in early stage cancer.

The immortal mice are busy placing bets :-)

Morning hasiba
With the AZN vaccine based on a chimp virus you should now be adept at climbing up to tackle the higher branches :-)

Morning Wild

Didn't Lindy once imply that men are such wimps and one even withdrew from the SCIB1 trial complaining of a sore arm.

I agree with you Knowlesi. In my experience algo trades tend to many frequent trades all for the same number of shares.
And as you say you really need a tight spread. It used to happen to a Nasdaq share I was in and you would see 10s and sometimes 100s of trades all for the same amount.

Probably Glycans mAbs and Avidimab were considered non-core until Redmile's second investment.

Ideal for a dose escalation study I would have thought :-)

Hi Max
The relevant RNS is a bit ambiguous
https://www.lse.co.uk/rns/SCLP/funds-awarded-by-innovate-uk-for-covid-19-vaccine-1wibac8ii81x7dn.html

"The funding will be used to initiate a Phase 1 clinical trial ("COVIDITY") during 2021."

Does this mean to get as far as being ready to start a P1 trial or actually complete a P1 trial?
I don't believe that a P1 trial would cost that much in these circumstances since it would take place using healthy individuals.
I would imagine, apart from the obvious safety aspect, Lindy would be keen to measure populations of antibodies and, of course, T Cells.

But, as crumbs asks, would CEPI necessarily wait until a P1 is completed before making a decision on Covidity?

It does seem to be a great situation that Scancell find themselves in.
Immunobody is a powerful platform designed to activate specific T cells with enough potency to have a great chance of being effective against cancer.

But it is the memory T Cells that seem to be the most important facet of Immunobody in the case of Covidity.
This is an entirely natural process whereby a proportion of the T Cells activated by Immunobody become memory cells as opposed to effector cells.

The SCIB1 trial was shown to produce a memory effect so it is logical to expect that Covidity will also produce a memory effect. Both vaccines utilise the exact same mechanism but aimed at different sets of T Cells.

It looks like the strength of the memory may well determine the duration of immunity.

https://www.bmj.com/content/371/bmj.m4838

"These studies and others31012 offer strong evidence that T cell immune responses are sustained, even in the face of declining or undetectable antibodies, implying that some immunity persists. It is possible, but as yet unconfirmed, that immunity might last even longer, as T cell responses to SARS-CoV-1 and MERS-CoV have been found several years after infection.13 The evidence from new studies, interim results from phase III vaccine trials, and previous data from phase I and phase II trials support the notion that memory T cell responses to the vaccines, along with B cell antibody responses, should provide good and possibly enduring immunity to SARS-Cov-2. This, together with continuing public health measures, should help lay a pathway out of the pandemic."

The potency of the T Cells activated by Covidity is no doubt one of the aspects that is attracting attention from CEPI.
Of course, there is the little matter of human trials to prove the T Cell potency in humans.

The serious

https://www.scientificamerican.com/article/eight-persistent-covid-19-myths-and-why-people-believe-them/

and the frivolous

https://www.elle.com/uk/life-and-culture/a31892113/coronavirus-conspiracy-theories/

I am still waiting for my portion of the giant Wembley lasagne to be delivered. I have concocted a sauce based on cow's urine, cocaine, garlic and coconut oil to go with it.

Of course the elephants can travel freely throughout Zambia because they have herd immunity

Thanks for that Awonda

You want to find the very best epitopes to go after regardless of whether it expressed by cancer cells, or virus molecules or virus infected cells.

We know that the Covid19 spike protein evolves so it is just a question of running the software against different versions of the protein.
I take your point that the Baseimmune software has taken it a step further by keeping information about all the known variants so it can do things more efficiently like;
a) this epitope still exists on all variants
b) this epitope is missing on specific variants.

Interesting stuff and extremely useful. I would imagine it is also strong linked to the work Deepmind are doing on protein folding.

https://deepmind.com/blog/article/alphafold-a-solution-to-a-50-year-old-grand-challenge-in-biology

I would imagine Lindy is interested in both technologies.

They weren't kidding when they said the software is freely available

https://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py#forms::PEP-FOLD3

No doubt Lindy and her team feed back information and suggested improvements to the people at Paris University.
Another Scancell pound shop branch, this time with a pound off the normal price :-)

This was the link you posted a few days ago

https://www.thecreatorfund.com/creator/baseimmune/

You might be interested to know that Scancell have also been using computer algorithms to find protein epitopes for some time. They created a poster for this at a Paris conference (International Cancer Immunotherapy Conference, Paris, 25-28 September 2019)

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-2019-peptide-selection-final.pdf

"Analysis was performed using PEP-FOLD 3 software4, a freely available online
resource. Peptide folding analysis showed good responses often correlated with a spiral
shape"

Thanks for the link Northern
I have just watched the presentation and I was a bit surprised that JLP was consistently referred to as a miner with all the increased risks are attached to being a miner as opposed to a processor of tailings.
But what was interesting was the view of the presenter that rhodium, platinum and palladium prices will remain strong for a number of years.

I quite like the personal bickering. It is not quite the same entertainment value as when Ruck and Inan were going at it sometimes for days on end.
On the beaufort scale we are currently at about 3.

Hi violindog

When we talk about delivery on this BB, more often than not we are talking about how the vaccine finds its way into muscle cells and also APCs once it has been injected into the body.

https://committees.parliament.uk/writtenevidence/4946/pdf/

"DNA vaccines are simple and fast to manufacture compared to other vaccine
approaches but they require specialist delivery devices such as electroporation
to ensure cellular transfection. To overcome this we have developed a simple
non-toxic peptide delivery system which is as effective as electroporation and
superior to lipid-based delivery systems."

So the vaccine will be conjugated with the peptide delivery system to achieve good penetration into the target cells. The relevant work is to find the best peptides to achieve this.